Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Moon Jong | - |
dc.contributor.author | Huang, Yuanjian | - |
dc.contributor.author | Park, Jae-Il | - |
dc.date.accessioned | 2024-01-24T11:30:21Z | - |
dc.date.available | 2024-01-24T11:30:21Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90211 | - |
dc.description.abstract | Simple Summary Therapeutic targeting of Wnt has long been suggested for gastrointestinal (GI) cancer treatment because deregulation of Wnt signaling is associated with GI cancers. However, therapeutic targeting of Wnt is still challenging because of the pleiotropic roles of Wnt signaling in the human body. Thus, targeting strategies of Wnt signaling are continuously evolving. The current flows of targeting Wnt signaling for cancer treatment are focused on increasing the specificity of drugs and combinatory treatment with other cancer drugs that minimize side effects and increase efficacy. Additionally, increased knowledge about the beta-catenin paradox has expanded the cases that can be treated with Wnt targeting therapy, not strictly considering Wnt upstream and downstream mutations. Here, we discuss these evolving views of targeting Wnt signaling and describe examples of current clinical trials. Wnt signaling governs tissue development, homeostasis, and regeneration. However, aberrant activation of Wnt promotes tumorigenesis. Despite the ongoing efforts to manipulate Wnt signaling, therapeutic targeting of Wnt signaling remains challenging. In this review, we provide an overview of current clinical trials to target Wnt signaling, with a major focus on gastrointestinal cancers. In addition, we discuss the caveats and alternative strategies for therapeutically targeting Wnt signaling for cancer treatment. | - |
dc.format.extent | 28 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views | - |
dc.type | Article | - |
dc.identifier.wosid | 000601835300001 | - |
dc.identifier.doi | 10.3390/cancers12123638 | - |
dc.identifier.bibliographicCitation | CANCERS, v.12, no.12, pp 1 - 28 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85097250125 | - |
dc.citation.endPage | 28 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | CANCERS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 12 | - |
dc.type.docType | Review | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Wnt signaling | - |
dc.subject.keywordAuthor | &#946 | - |
dc.subject.keywordAuthor | -catenin | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | gastrointestinal cancers | - |
dc.subject.keywordAuthor | therapeutic targeting of Wnt signaling | - |
dc.subject.keywordAuthor | &#946 | - |
dc.subject.keywordAuthor | -catenin paradox | - |
dc.subject.keywordAuthor | molecular targeting | - |
dc.subject.keywordPlus | SMALL-MOLECULE INHIBITOR | - |
dc.subject.keywordPlus | BETA-CATENIN DEGRADATION | - |
dc.subject.keywordPlus | WNT/BETA-CATENIN | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | AUTOPHAGY INHIBITION | - |
dc.subject.keywordPlus | TANKYRASE INHIBITOR | - |
dc.subject.keywordPlus | FRIZZLED HOMOLOGS | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.